NL-OMON29559
Not yet recruiting
Not Applicable
Therapeutic drug monitoring: Toward tailored dosing of adalimumab in rheumatoid arthritis.
ReumafondsReade, centrum voor revalidatie en reumatologie0 sites102 target enrollmentTBD
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- rheumatoid arthritisadalimumabtherapeutic drug monitoring
- Sponsor
- ReumafondsReade, centrum voor revalidatie en reumatologie
- Enrollment
- 102
- Status
- Not yet recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
/A
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. RA according to the ACR 1987 criteria;
- •2\. Adalimumab treatment for at least 28 weeks;
Exclusion Criteria
- •Scheduled surgery in the next 6 months or other pre planned reasons for treatment discontinuation.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
therapeutic drug monitoring: towards tailored dosing of adalimumab in rheumatoid arthritisrheumatoide arthritis10003816NL-OMON41716Reade, centrum voor Revalidatie en Reumatologie55
Not yet recruiting
Not Applicable
Will pazopanib dose individualization result in less variability in pazopanib bloodconcentrations between individuals.Cancer,Solid tumorPhase INL-OMON22313eiden University Medical Center13
Completed
Not Applicable
Therapeutic Drug Monitoring to Individualize the Dosing of pazopanib: a Randomized Pharmacokinetic Feasibility Studyadvanced tumors for which no treatment options are availablerenal cell cancer10038588NL-OMON37356eids Universitair Medisch Centrum13
Completed
Phase 3
Therapeutic drug monitoring-based dose optimisation of piperacillin in patients with severe sepsis or septic shock to investigate effects on organ functions and survival: a prospective, multicenter, randomized controlled trialR65.1R57.2Systemic Inflammatory Response Syndrome of infectious origin with organ failureSeptic shockDRKS00011159Friedrich-Schiller-Universität Jena254
Active, not recruiting
Phase 1
Measurement of the blood concentration of the antibiotic piperacillin and individual drug dosage in patients with febrile neutropenia after chemotherapyPatients with febrile neutropenia after myelo-suppressive chemotherapy treated with piperacillin/tazobactamTherapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]EUCTR2016-002388-33-DEFriedrich-Schiller-University Jena208